Financhill
Buy
57

GDERF Quote, Financials, Valuation and Earnings

Last price:
$205.25
Seasonality move :
0%
Day range:
$205.25 - $205.25
52-week range:
$97.00 - $205.25
Dividend yield:
0.04%
P/E ratio:
129.11x
P/S ratio:
10.48x
P/B ratio:
4.86x
Volume:
204
Avg. volume:
1.9K
1-year change:
111.6%
Market cap:
$48.2B
Revenue:
$4.4B
EPS (TTM):
$1.59

Analysts' Opinion

  • Consensus Rating
    No consensus rating exists at this time due to lack of analyst coverage.
  • Price Target Downside
    No price target exists because of limited analyst coverage.
  • Price Target Upside
    Similarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.

Fair Value

  • According to the consensus of 0 analysts, Galderma Group AG has -- downside to fair value with a price target of -- per share.

GDERF vs. S&P 500

  • Over the past 5 trading days, Galderma Group AG has underperformed the S&P 500 by -1.41% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Galderma Group AG does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Galderma Group AG has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Galderma Group AG reported revenues of --.

Earnings Growth

  • Galderma Group AG has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Galderma Group AG reported earnings per share of --.
Enterprise value:
39.8B
EV / Invested capital:
--
Price / LTM sales:
10.48x
EV / EBIT:
56.82x
EV / Revenue:
8.49x
PEG ratio (5yr expected):
--
EV / Free cash flow:
54.34x
Price / Operating cash flow:
66.67x
Enterprise value / EBITDA:
39.44x
Gross Profit (TTM):
$3.2B
Return On Assets:
2.98%
Net Income Margin (TTM):
8.12%
Return On Equity:
4.9%
Return On Invested Capital:
3.62%
Operating Margin:
--
Trailing 12 Months Fiscal Quarters
Period Ending 2023-12-25 2024-12-25 2024-12-25
Income Statement
Revenue -- -- -- -- --
Gross Profit -- -- -- -- --
Operating Income -- -- -- -- --
EBITDA -- -- -- -- --
Diluted EPS -- -- -- -- --
Period Ending 2021-06-30 2022-06-30 2023-06-30 2024-06-30 2025-06-30
Balance Sheet
Current Assets -- -- -- $1.8B $1.9B
Total Assets -- -- -- $12.6B $12.9B
Current Liabilities -- -- -- $1.5B $1.8B
Total Liabilities -- -- -- $4.9B $5.1B
Total Equity -- -- -- $7.6B $7.7B
Total Debt -- -- -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2023-12-25 2024-12-25 2024-12-25
Cash Flow Statement
Cash Flow Operations -- -- -- -- --
Cash From Investing -- -- -- -- --
Cash From Financing -- -- -- -- --
Free Cash Flow -- -- -- -- --
GDERF
Sector
Market Cap
$48.2B
$28M
Price % of 52-Week High
100%
51.03%
Dividend Yield
0.04%
0%
Shareholder Yield
1.01%
-1.54%
1-Year Price Total Return
111.6%
-17.48%
Beta (5-Year)
--
0.518
Dividend yield:
0.04%
Annualized payout:
$0.00
Payout ratio:
-10.85%
Growth streak:
0 years

Technicals

8-day SMA
Sell
Level $205.25
200-day SMA
Buy
Level $153.65
Bollinger Bands (100)
Buy
Level 164.69 - 192.95
Chaikin Money Flow
Sell
Level -7.1K
20-day SMA
Buy
Level $201.93
Relative Strength Index (RSI14)
Buy
Level 82.93
ADX Line
Buy
Level 53.73
Williams %R
Sell
Level 0
50-day SMA
Buy
Level $188.24
MACD (12, 26)
Buy
Level 5.41
25-day Aroon Oscillator
Buy
Level 48
On Balance Volume
Sell
Level -56.7K

Financial Scores

Buy
Altman Z-Score (Annual)
Level (4.0412)
Buy
CA Score (Annual)
Level (0.0179)
Buy
Beneish M-Score (Annual)
Level (-2.2961)
--
Momentum Score
Level (--)
Buy
Ohlson Score
Level (-1.9724)
Buy
Piotroski F Score (Annual)
Level (8)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Galderma Group AG engages in the provision of science-based premium dermatology solutions. The firm is also involved in delivering a synergistic portfolio of flagship brands spanning the full spectrum of the fast-growing self-care dermatology market. The company was founded in 1981 and is headquartered in Zug, Switzerland.

Stock Forecast FAQ

In the current month, GDERF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The GDERF average analyst price target in the past 3 months is --.

  • Where Will Galderma Group AG Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Galderma Group AG share price will drop to -- per share over the next 12 months.

  • What Do Analysts Say About Galderma Group AG?

    Analysts are divided on their view about Galderma Group AG share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Galderma Group AG is a Sell and believe this share price will rise from its current level to --.

  • What Is Galderma Group AG's Price Target?

    The price target for Galderma Group AG over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is GDERF A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Galderma Group AG is a --. 0 of 0 analysts rate the stock a -- at this time.

  • How Can I Buy Shares Of GDERF?

    You can purchase shares of Galderma Group AG via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Galderma Group AG shares.

  • What Is The Galderma Group AG Share Price Today?

    Galderma Group AG was last trading at $205.25 per share. This represents the most recent stock quote for Galderma Group AG. Yesterday, Galderma Group AG closed at $205.25 per share.

  • How To Buy Galderma Group AG Stock Online?

    In order to purchase Galderma Group AG stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is DocuSign Stock Undervalued?
Is DocuSign Stock Undervalued?

Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…

Is SentinelOne Stock Undervalued?
Is SentinelOne Stock Undervalued?

Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…

Is Broadcom Stock on Sale?
Is Broadcom Stock on Sale?

Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…

Stock Ideas

Buy
57
Is NVDA Stock a Buy?

Market Cap: $4.6T
P/E Ratio: 64x

Buy
55
Is AAPL Stock a Buy?

Market Cap: $4T
P/E Ratio: 37x

Buy
61
Is GOOG Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 39x

Alerts

Buy
80
TVTX alert for Dec 25

Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.

Buy
68
KOD alert for Dec 25

Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.

Buy
64
ZCSH alert for Dec 25

Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock